Dopamine Neuron Stimulating Actions of a GDNF Propeptide

PLoS ONE

Volumn 5, Issue 3, 2010, Pages

  Bradley, Luke H ^a   Fuqua, Josh ^a   Richardson, April ^a   Cholewo, Jadwiga Turchan ^a   Ai, Yi ^a   Kelps, Kristen A ^a   Glass, John D ^b   He, Xiuquan ^a   Zhang, Zhiming ^a   Grondin, Richard ^a   Littrell, O Meagan ^a   Huettl, Peter ^a   Pomerleau, Francois ^a   Gash, Don M ^a   Gerhardt, Greg A ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; DOPAMINE; GFRA1 PROTEIN, RAT; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR RECEPTOR; ISOFLURANE; NERVE GROWTH FACTOR; OXIDOPAMINE;

ANIMAL; ARTICLE; CHEMISTRY; DISEASE MODEL; FISCHER 344 RAT; MALE; METABOLISM; NERVE CELL; RAT; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA;

ANIMALS; APOMORPHINE; DISEASE MODELS, ANIMAL; DOPAMINE; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR RECEPTORS; ISOFLURANE; MALE; NERVE GROWTH FACTORS; NEURONS; OXIDOPAMINE; RATS; RATS, INBRED F344; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA;

EID: 79551586768     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0009752     Document Type: Article

References (52)

1. Hornykiewicz O, Kish SJ (1987) Biochemical pathophysiology of Parkinson's disease. Adv Neurol 45: 19-34.
2. Lin L-F, Doherty DH, Lile JD, Bektesh S, Collins F (1993) GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260: 1130-1132.
3. Gash DM, Zhang ZM, Ovadia A, Cass WA, Yi A, et al. (1996) Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380: 252-255.
4. Gill SS, Patel NK, Hotton GR, O'Sullivan K, McCarter R, et al. (2003) Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nature Medicine 9: 589-595.
5. Slevin JT, Gerhardt GA, Smith CD, Gash DM, Kryscio R, et al. (2005) Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg. 102: 216-222.
6. Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, et al. (2006) Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 59: 459-466.
7. Hoffer BJ, Hoffman A, Bowenkamp K, Huettl P, Hudson J, et al. (1994) Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci Lett 182: 107-111.
8. Grondin R, Zhang Z, Yi A, Cass W, Maswood N, et al. (2002) Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain 125: 2191-2201.
9. Ibáñez CF (2002) Jekyll-Hyde neurotrophins: the story of NGF. Trends Neurosci. 25: 284-286.
10. Suter U, Heymach JV, Jr., Shooter EM (1991) Two conserved domains in the NGF propeptide are necessary and sufficient for the biosynthesis of correctly processed and biologically active NGF. EMBO J 10: 2395-2400.
11. Rattenholl A, Ruoppolo M, Flagiello A, Monti M, Vinci F, et al. (2001) Prosequence assisted folding and disulfide bond formation of human nerve growth factor. J Mol Biol 305: 523-533.
12. Lee R, Kermani P, Teng KK, Hempstead BL (2001) Regulation of cell survival by secreted proneurotrophins. Science 294: 1945-1948.
13. Nykjaer A, Lee R, Teng KK, Jansen P, Madsen P, et al. (2004) Sortilin is essential for proNGF-induced neuronal cell death. Nature 427: 843-848.
14. Teng HK, Teng KK, Lee R, Wright S, Tevar S, et al. (2005) ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR and sortilin. J Neuro 25: 5455-5463.
15. Immonen T, Alakuijala A, Hytonen M, Sainio K, Poteryaev D, et al. (2008) A proGDNF-related peptide BEP increases synaptic excitation in rat hippocampus. Exp Neurol 210: 793-796.
16. Choi HK, Won LA, Kontur PJ, Hammond DN, Fox AP, et al. (1991) Immortalization of embryonic mesencephalic dopaminergic neurons by somatic cell fusion. Brain Res 552: 67-76.
17. Schubert D, Heinemann S, Carlisle W, Tarikas H, Kimes B, et al. (1974) Clonal cell lines from the rat central nervous system. Nature 249: 224-227.
18. Hebert MA, van Horne CG, Hoffer BJ, Gerhardt GA (1996) Functional effects of GDNF in normal rat striatum: Presynaptic studies using in vivo electrochemistry and microdialysis. J Pharmacol Exper Ther 279: 1181-1190.
19. Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, et al. (2002) Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci 15: 120-132.
20. Hall ME, Hoffer BJ, Gerhardt GA (1989) Rapid and sensitive determination of catecholamines in small tissue samples by High-Performance Liquid-Chromatography coupled with dual-electrode coulometric electrochemical detection. LC GC-Mag Sep Sci 7: 258-265.
21. Hudson JL, van Horne CG, Strömberg I, Brock S, Clayton J, et al. (1993) Correlation of apomorphine-induced and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Brain Res 626: 167-174.
22. York B, Lou D, Panettieri RA, Jr., Krymskaya VP, Vanaman TC, et al. (2005) Cross-talk between tuberin, calmodulin and estrogen signaling pathways. FASEB J 19: 1202-4.
23. Apweiler R, Bairoch A, Wu CH (2004) Protein sequence databases. Curr Opin Chem Biol 8: 76-80.
24. Shilov IV, Seymour SL, Patel AA, Loboda A, Tang WH, et al. (2007) The paragon algorithm, a next generation search engine that uses sequence temperature values and features probabilities to identify peptides from tandem mass spectra. Mol Cell Proteomics 6: 1638-1655.
25. Salvatore MF, Zhang JL, Large DM, Wilson PE, Gash CR, et al. (2004) Striatal GDNF administration increases tyrosine hydroxylase phosphorylation in the rat striatum and substantia nigra. J Neurochem 90: 245-254.
26. Salvatore MF, Gerhardt GA, Dayton RD, Klein RL, Stanford JA (2009) Bilateral effects of unilateral GDNF administration on dopamine-and GABAregulating proteins in the rat nigrostriatal system. Exp Neurol 219: 197-207.
27. Hebert MA, Gerhardt GA (1997) Behavioral and neurochemical effects of intranigral administration of glial cell line-derived neurotrophic factor on aged Fischer 344 rats. J Pharm Exp Thera 282: 760-768.
28. Winkler C, Sauer H, Lee CS, Bjorklund A (1996) Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson's disease. J Neurosci 16: 7206-7215.
29. Kragten E, Lalande I, Zimmermann K, Roggo K, Schindler P, et al. (1998) Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl. J Biol Chem 273: 5821-5828.
30. Carlile GW, Chalmers-Redman RM, Tatton NA, Pong A, Borden KE, et al. Reduced apoptosis after nerve growth factor and serum withdrawal: conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer. Mol Pharmacol 57: 2-12.
31. Tatton W, Chalmers-Redman R, Tatton N (2003) Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B. J Neural Transm 110: 509-15.
32. Hara MR, Thomas B, Cascio MB, Bae B-I, Hester LD, et al. (2006) Neuroprotection by pharmacologic blockade of the GAPDH death cascade. Proc Natl Acad Sci USA 103: 3887-3889.
33. Tatton NA (2000) Increased caspase 3 and bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease. Exp Neurol 166: 29-43.
34. Hara MR, Agrawal N, Kim SF, Cascia MB, Fujimuro M, et al. (2005) S-nitrosylated GAPDH initiates apoptotic cell death by nuclear translocation following Siah1 binding. Nat Cell Biol 7: 665-674.
35. Schapira AH, Gu M, Taanman JW, Tabrizi SJ, Seaton T, et al. (1998) Mitochondria in the etiology and pathogenesis of Parkinson's disease. Ann Neurol 44: S89-98.
36. Mattson MP, Pedersen WA, Duan W, Culmsee C, Camandola S (1999) Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer's and Parkinson's diseases. Ann NY Acad Sci 893: 154-175.
37. Moore DJ, West AB, Dawson VL, Dawson TM (2005) Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci 28: 57-87.
38. Henchcliffe C, Beal MF (2008) Mitochondrial biology and oxidative stress in Parkinson's disease pathogenesis. Nat Clin Pract Neurol 4: 600-609.
39. Büeler H (2009) Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease. Exp Neurol 218: 235-246.
40. Rueggs UT, Burgess GM (1989) Staurosporine, K-252 and UCN-01: potent but nonspecific inhibitors of protein kinases. Trends Pharmacol Sci 10: 218-220.
41. Nicholls DG, Budd SL (2000) Mitochondria and neuronal survival. Physiol Rev 80: 315-360.
42. Goldstein JC, Munoz-Pinedo C, Ricci JE, Adams SR, Kelkar A, et al. (2005) Cytochrome c is released in a single step during apoptosis. Cell Death Differ 12: 435-462.
43. Yu LY, Jokitalo E, Sun YF, Mehlen P, Lindholm D, et al. (2003) GDNFdeprived sympathetic neurons die via a novel nonmitochondrial pathway. J Cell Biol 163: 987-997.
44. Yu LY, Saarma M, Arumäe U (2008) Death receptors and caspases but not mitochondria are activated in the GDNF-or BDNF-deprived dopaminergic neurons. J Neurosci 28: 7467-7475.
45. Ibáñez CF (1998) Emerging themes in structural biology of neurotrophic factors. Trends Neurosci 21: 438-44.
46. Thorne RG, Frey WHI (2001) Delivery of neurotrophic factors to the central nervous system: Pharmacokinetic considerations. Clin Pharmacokinet 40: 907-946.
47. Born J, Lange T, Kern W, McGregor GP, Bickel U, et al. (2002) Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 5: 514-516.
48. Mahato RI, Narang AS, Thoma L, Miller DD (2003) Emerging trends in oral delivery of peptide and protein drugs. Crit Rev Ther Drug Carrier Syst 20: 153-214.
49. Hoffman AF, van Horne CG, Eken S, Hoffer BJ, Gerhardt GA (1997) In vivo microdialysis studies of somatodendritic dopamine release in the rat substantia nigra: effects of unilateral 6-OHDA lesions and GDNF. Exp Neurol 147: 130-141.
50. Chao MV, Bothwell M (2002) Neurotrophins: To cleave or not to cleave. Neuron 33: 9-12.
51. Dicou E, Pflug B, Magazin M, Lehy T, Djakiew D, et al. (1997) Two peptides derived from the nerve growth factor precursor are biologically active. J Cell Biol 136: 389-98.
52. Dicou E (2006) Multiple biological activities for two peptides derived from the nerve growth factor precursor. Biochem Biophys Res Commun 347: 833-837.